IBDEI39P ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54913,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,54913,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,54913,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,54914,0)
 ;;=C92.40^^256^2775^20
 ;;^UTILITY(U,$J,358.3,54914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54914,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,54914,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,54914,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,54915,0)
 ;;=D56.0^^256^2775^21
 ;;^UTILITY(U,$J,358.3,54915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54915,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,54915,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,54915,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,54916,0)
 ;;=D63.1^^256^2775^23
 ;;^UTILITY(U,$J,358.3,54916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54916,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,54916,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,54916,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,54917,0)
 ;;=D63.0^^256^2775^24
 ;;^UTILITY(U,$J,358.3,54917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54917,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,54917,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,54917,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,54918,0)
 ;;=D63.8^^256^2775^22
 ;;^UTILITY(U,$J,358.3,54918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54918,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,54918,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,54918,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,54919,0)
 ;;=C22.3^^256^2775^25
 ;;^UTILITY(U,$J,358.3,54919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54919,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,54919,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,54919,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,54920,0)
 ;;=D61.9^^256^2775^26
 ;;^UTILITY(U,$J,358.3,54920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54920,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,54920,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,54920,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,54921,0)
 ;;=D56.1^^256^2775^28
 ;;^UTILITY(U,$J,358.3,54921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54921,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,54921,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,54921,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,54922,0)
 ;;=C83.79^^256^2775^29
 ;;^UTILITY(U,$J,358.3,54922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54922,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,54922,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,54922,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,54923,0)
 ;;=C83.70^^256^2775^30
 ;;^UTILITY(U,$J,358.3,54923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54923,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,54923,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,54923,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,54924,0)
 ;;=D09.0^^256^2775^37
 ;;^UTILITY(U,$J,358.3,54924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54924,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,54924,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,54924,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,54925,0)
 ;;=D06.9^^256^2775^38
 ;;^UTILITY(U,$J,358.3,54925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54925,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,54925,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,54925,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,54926,0)
 ;;=D06.0^^256^2775^40
 ;;^UTILITY(U,$J,358.3,54926,1,0)
 ;;=^358.31IA^4^2
